Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Receivables (2016 - 2019)

Aptevo Therapeutics' Receivables history spans 5 years, with the latest figure at $7.0 million for Q4 2019.

  • For Q4 2019, Receivables rose 34.52% year-over-year to $7.0 million; the TTM value through Dec 2019 reached $7.0 million, up 34.52%, while the annual FY2019 figure was $7.0 million, 34.52% up from the prior year.
  • Receivables for Q4 2019 was $7.0 million at Aptevo Therapeutics, down from $7.9 million in the prior quarter.
  • Across five years, Receivables topped out at $8.5 million in Q2 2016 and bottomed at $307000.0 in Q4 2016.
  • The 5-year median for Receivables is $5.5 million (2018), against an average of $4.8 million.
  • The largest annual shift saw Receivables tumbled 95.24% in 2016 before it surged 1074.62% in 2018.
  • A 5-year view of Receivables shows it stood at $6.5 million in 2015, then crashed by 95.24% to $307000.0 in 2016, then skyrocketed by 597.39% to $2.1 million in 2017, then soared by 143.81% to $5.2 million in 2018, then surged by 34.52% to $7.0 million in 2019.
  • Per Business Quant, the three most recent readings for APVO's Receivables are $7.0 million (Q4 2019), $7.9 million (Q3 2019), and $7.4 million (Q2 2019).